Is Vismodegib on the market?

Vismodegib (Vismodegib) is a drug used to treat basal cell carcinoma (BCC) with the trade name Erivedge. Vimodegib was approved for marketing by the U.S. Food and Drug Administration (FDA) in January 2012. It is the first FDA-approved agent targeting the Hedgehog signaling pathway , which is involved in many basal cell carcinomas. Basal cell carcinoma is the most common non-melanoma skin cancer (NMSC), accounting for more than half of all NMSC diagnoses.

In July 2013, it was approved by the European Medicines Agency (EMA), which concluded that the benefits of vismodegib in patients with locally advanced and metastatic disease have been demonstrated and that side effects can be controlled. Because vismodegib disrupts mechanisms in the early stages of development of the unborn baby, both men and women receiving vismodegib need to take appropriate steps to prevent pregnancy during and after stopping treatment. Vimodegib selectively binds to and inhibits the transmembrane protein smooth homolog (SMO), thereby inhibiting theHedgehog signaling pathway. The use of vismodegib was not associated with clinically significant QT prolongation after 7 days of dosing at 150 mg once daily.

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.